Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are currently considered the same entity, but controversy remains over whether CLL and SLL should be treated similarly. We assessed whether characteristics of patients with CLL and SLL differ in ways other than the absolute lymphocyte count (ALC) and evaluated treatment outcomes and prognostic factors.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are viewed as similar entities by the WHO. 1 Histologically and immunophenotypically, CLL and SLL are identical, but patients with CLL, by definition, have more marked peripheral blood involvement. [2] [3] [4] An absolute lymphocyte count (ALC) of 5 ϫ 10 9 /L has been used to distinguish SLL from CLL (with SLL defined by an ALC Ͻ 5 ϫ 10 9 /L). This cutoff is somewhat arbitrary, however, and has never been evaluated definitively.
Homing receptors may explain the clinical differences between CLL and SLL. SLL tissue samples are reported to be positive for L-selectin, CD44, and CD11c/CD18, but they lack lymphocyte functionassociated antigen-3 (LFA-3) and intercellular adhesion molecule-1.
2 LFA-1 is expressed by SLL, but not by CLL cells. 3, 5 The clinical course of CLL/SLL varies widely. The indolent clinical behavior of SLL has often led to the approach of deferring treatment in asymptomatic patients until progressive disease becomes evident. 6 Patients with SLL are eventually offered therapies developed for other indolent lymphomas, the most common being follicular lymphoma, even though the biology of SLL differs from that of follicular lymphomas. Treatment of CLL is also deferred until indications for therapeutic intervention are present. In recent years, combination therapies with nucleoside analogs and rituximab have led to improved outcomes in SLL and CLL, but there is still no consensus as to the optimal treatments for these diseases.
To assess whether the presenting characteristics of patients with CLL/SLL differ in ways other than the ALC and to address which therapy is best for CLL and SLL patients, we retrospectively analyzed data from the largest series of CLL/SLL patients to date. The secondary end point was to identify prognostic factors predicting clinical outcomes.
METHODS
We searched an electronic database of 2,359 consecutive, previously untreated patients designated as having either CLL or SLL who presented to The University of Texas M.D. Anderson Cancer Center Department of Leukemia or Department of Lymphoma/Myeloma (Houston, TX) between 1985 and 2005. All patient records were reviewed to determine presenting features, treatment, and clinical outcomes. A waiver of informed consent and a waiver of authorization were granted by the institutional review board.
Diagnosis
Diagnosis of CLL/SLL was made by morphologic examination with ancillary immunophenotyping. The neoplastic cells were small lymphocytes of B-cell lineage, positive for CD5 and CD19 or CD20 in all cases. In most cases more recently assessed, surface immunoglobulin (Ig) and CD20 expression was dim, CD23 was usually positive, and FMC-7 and CD79b were usually negative. All cases assessed were negative for cyclin D1 and lacked cytogenetic or molecular evidence of t(11;14)(q13;q32) or of t(14;18)(q32;q21) involving bcl-2. Pseudofollicles (proliferation centers) could be detected in all excisional lymph node biopsy specimens and in a small subset of bone marrow biopsy specimens with extensive involvement.
Therapy
Staging and treatment were determined after review of all clinical, laboratory, and pathologic data in a multidisciplinary conference. Patients were treated systemically if they had the standard indications for therapeutic intervention in CLL/SLL (Appendix, online only). 7 Even in the absence of these indications, treatment was sometimes initiated if the patient and/or physician were uncomfortable with deferral of therapy. Regimens varied over the years and according to the department in which the patient was seen. Assignment to different treatments was based on therapy availability, patient preference, and physician discretion. Treatment regimens included in the analysis were fludarabine with or without prednisone (F Ϯ P) [8] [9] [10] ; fludarabine and cyclophosphamide (FC)   11   ; fludarabine and mitoxantrone   12 ; fludarabine, cyclophosphamide, and rituximab (FCR) 13 ; fludarabine, mitoxantrone, dexamethasone, and rituximab (R-FND) 14 ; fludarabine, cyclophosphamide, mitoxantrone, and rituximab (R-FCM) 15 ; and rituximab with or without granulocyte-macrophage colony-stimulating factor.
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End Points and Statistical Methods
In patients with CLL, the response criteria were those defined by the National Cancer Institute (NCI)-sponsored Working Group. 17 In patients with SLL, the response and end point assessments conformed to the NCI International Working Group response criteria.
18 Survival was measured from the time of presentation at M.D. Anderson until death from any cause or last follow-up. Failure-free survival (FFS) was measured from the start of treatment until disease progression, relapse, or death. To assess treatment outcomes, survival was measured from the start of treatment until death from any cause or last follow-up. The 2 test and t test were used in univariate analyses of categoric and continuous variables, respectively. Survival curves were estimated using the Kaplan-Meier method, and survival between groups was compared using the two-sided log-rank test. The multivariate Cox proportional hazards regression model was used to examine risk factors related to survival or FFS after adjusting for other factors. A randomly selected training set and a validation set of patients were used to perform multivariate analyses for survival. We also used a "bootstrapping" method in which we repeatedly (1,000 times) randomly selected 67% of the total population and assessed in what proportion of the 1,000 samples the Cox model identified a covariate as having independent prognostic significance. Those covariates found to be significant in the training and validation sets and noted to be independently significant in at least 75% of the randomly selected 1,000 bootstrapping sets were used to design a model to predict an individual patient's risk of death: the CLL/SLL score. P Ͻ .05 was considered to be statistically significant.
RESULTS
Patient Characteristics
A total of 2,126 patients were included in the analysis; 233 patients were excluded because, on subsequent assessment, the disease was better characterized as mantle-cell lymphoma, marginal zone lymphoma, or hairy cell leukemia; data were incomplete; or the patient was lost to follow-up.
The median age was 58 years (range, 17 to 90 years). There was a male preponderance (61%). A total of 312 patients (15%) had an ALC less than 5 ϫ 10 9 /L, along with lower rates of organomegaly and lymph node involvement and less extensive bone marrow infiltration than patients with ALC at least 5 ϫ 10 9 /L. Patients with ALC less than 5 ϫ 10 9 /L also had lower rates of genomic aberrations by cytogenetic analysis (13% v 27%; P ϭ .0002) and fluorescence in situ hybridization (FISH) analysis (55% v 71%; P ϭ .037) and higher rates of CD38 expression (36% v 22%; P ϭ .0002) and Ig heavy chain variable region gene (IgV H ) mutations (76% v 55%; P ϭ .034) compared with patients with higher ALCs.
Time to Treatment
Overall, 51% of patients required therapy. The median time from diagnosis of CLL/SLL to treatment was 4.2 years (95% CI, 3.8 to 4.7 years; range, 0 to 31.3 years). The median time to treatment was 3.8 years (range, 0 to 11.5 years) in patients with ALC less than 5 ϫ 10 9 /L (5.2 years for patients treated in the Leukemia Department and 1.3 years for those treated in the Lymphoma Department) and 4.3 years (range, 0 to 31.3 years) in patients with ALC at least 5 ϫ 10 9 /L (Leukemia Department, 4.5 years; Lymphoma Department, 3.6 years; P ϭ .006).
Survival
The actuarial 5-year survival rate of the 2,126 patients was 79% (Fig 1A) . The median follow-up of survivors was 4.3 years. There was no difference in survival between patients presenting with an ALC less than 5 ϫ 10 9 /L and those with a higher ALC (P ϭ .493). Martingale residual plots for survival and FFS against ALC showed no clear cutoff for ALC. Differences in survival started to become evident using the ALC cutoff of 10 ϫ 10 9 /L (P ϭ .04) and were most striking using the cutoffs of 30 and 50 ϫ 10 9 /L (P Ͻ .0001 each). However, the cutoff of 30 ϫ 10 9 /L provides more clinical information because it has high statistical significance and divides the patient population into more balanced subgroups (Fig 1B; Fig A1A to A1E , online only). Bone marrow cytogenetic analysis demonstrated that 17p del with or without other abnormalities and 6q del with or without other abnormalities were each associated with shorter survival compared with the other cytogenetic groups (P Ͻ .0001 each; Fig 1C) . IgV H gene mutations appeared to be associated with higher survival rates (P ϭ .004), although this observation became evident only after 3 years ( Fig 1D) .
The correlations between the presenting characteristics and survival are shown in Table 1 . All of the listed characteristics, except for bone marrow involvement, CD38 and zeta-associated protein-70 (ZAP-70) expression, and FISH analysis, were significantly associated with survival.
Independent Prognostic Factors and the Prognostic Factor Model
Factors independently prognostic of survival in all patients with CLL/SLL are shown in Table 2 . Two thirds of the patients were randomly chosen to develop a model, and the remaining one third were used to validate the model. Cytogenetics, age, and ␤ 2 -microglobulin, albumin, and creatinine levels each independently affected survival both in the training and the validation sets (Tables A1 and A2) , whereas hepatomegaly, hemoglobin, sex, and ALC were prognostic in the training but not in the validation set. When the 2,126 patients were resampled to obtain 1,000 separate 1,417-patient data sets in each of which we fit a Cox model, cytogenetics, age, and ␤ 2 -microglobulin were each independently significant in 100% of the samples, albumin in 93%, and creatinine in 79%. The respective proportions for hepatomegaly, hemoglobin, sex, and ALC were 18%, 8%, 2%, and 1%.
On the basis of the results of both analyses, 17p del or 6q del with or without other cytogenetic abnormalities, age at least 60 years, ␤ 2 -microglobulin at least 2 mg/L, albumin less than 3.5 g/dL, and creatinine at least 1.6 mg/dL were used to develop a scoring system. Patient scores can range from 0 to 5. The Kaplan-Meier survival curves using the scores calculated from these five risk factors were similar using the training (Fig A2A, online only) and validation (Fig 2A) data sets. Application of this scoring system is shown in Figure A2B . At 5 years, 98%, 83%, 69%, and 21% of patients with 0, 1, 2, and 3 to 5 risk factors, respectively, are expected to be alive (Fig A2B) . When the Rai and Binet staging systems were added to the model, they were also significant, but were associated with lower relative risks (RRs) than the top five factors (RR ϭ 1.24 and 1.35, respectively). Survival by the Rai and Binet staging systems is shown in Figures 2B and 2C , respectively.
Therapy and Response
Overall, 1,041 patients were treated, and 965 patients were analyzed. Seventy-six patients who were treated with regimens other than those specified in the Methods section were excluded from the analysis.
To control for differences in clinical features, the 965 patients were analyzed according to their pretreatment characteristics (Table  3 ). There were differences between the treatment groups by sex; ALC; levels of hemoglobin, lactate dehydrogenase, and ␤ 2 -microglobulin; number of nodal sites; RAI stage; cytogenetics; IgV H mutational status; and CD38 positivity.
In univariate analysis, factors predicting overall response were hemoglobin levels higher than 11 g/dL (P Ͻ .0001), age less than 60 years (P ϭ .001), absence of 17p deletion or 6q deletion (P ϭ .01), and albumin levels at least 3.5 g/dL (P ϭ .05). There was no difference in response rates between patients with ALC less than 5 ϫ 10 9 /L and those with higher ALCs (P ϭ .73). In multivariate analysis, hemoglobin levels higher than 11 g/dL (P ϭ .0007), age less than 60 years (P ϭ .003), and absence of 17p deletion or 6q deletion (P ϭ .025) were independent factors predicting response. When treatment was included in the multivariate analysis, therapy with FCR, R-FCM, or R-FND was associated with higher response rates (P ϭ .0001).
FFS
The median FFS of the 965 patients was 3.2 years (95% CI, 3.0 to 3.5 years). FFS according to treatment and ALC is summarized in Table 4 . FFS was significantly higher in patients treated with FCR, /L and no bone marrow involvement were excluded from cytogenetic and FISH analyses. ‡This difference did not reach statistical significance in multivariate analyses probably because of the lower proportion of patients with low ALC, tested for these markers compared with that of patients with high ALC. Patients with missing data were excluded from the analysis.
§CD38 expression was highly correlated with unmutated status (P Ͻ .0001; data not shown). Follow-up is shorter in these patients and there are not many events; results may be different with longer follow-up. Abbreviations: CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; RR, relative risk (of death); CG, cytogenetic.
‫ء‬
When the cut-off of 5 ϫ 10 9 /L was used, absolute lymphocyte count was not statistically significant.
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R-FCM, or R-FND compared with other therapies (P Ͻ .0001; Fig  1E) . FCR, R-FCM, and R-FND were equally effective in patients with low (Ͻ 5 ϫ 10 9 /L) and high (Ն 5 ϫ 10 9 /L) ALCs. In univariate analysis, age less than 60 years (P Ͻ .0001), absence of 17p del with or without other abnormalities (P ϭ .0008), hemoglobin levels more higher 11 g/dL (P ϭ .009), RAI stage 0 to 2 (P ϭ .01), lower IgG levels (P ϭ .06), higher IgA levels (P ϭ .03), and absence of lymphadenopathy (P ϭ .03) predicted longer FFS. There was no significant difference in FFS between patients with ALC less than 5 ϫ 10 9 /L and those with higher ALCs (P ϭ .59). In multivariate analysis, pretreatment parameters that remained independently significant for longer FFS were age less than 60 years (P Ͻ .0001), absence of 17p del with or without other abnormalities (P ϭ .0037), and hemoglobin levels higher than 11 g/dL (P ϭ .03). When treatment was added to the model, therapy with FCR, R-FCM, or R-FND was also independently correlated with longer FFS (P Ͻ .0001).
Survival According to Treatment Regimen
The actuarial 5-year survival rate of the 965 treated patients was 76%. Although a stepwise improvement in survival was evident with the most recent treatment regimens (P Ͻ .0001), the follow-up period was short, and because the vast majority of the patients treated with FCR, R-FCM, or R-FND remain alive, comparisons by therapy cannot be evaluated at the present time.
Complete data on ZAP-70, IgV H gene mutational status, and FISH analysis were available in 219 patients (10.3%). However, the short follow-up period and the few events (seven deaths) preclude a valid analysis of these patients at the present time.
DISCUSSION
This report demonstrates that CLL and SLL are clinically similar diseases, with a few notable exceptions. A key finding of the current study is that therapy with FCR, R-FCM, or R-FND resulted in superior response and FFS rates compared with other regimens in both CLL and SLL. The current analysis also demonstrates that the prognostic relevance of the Rai and Binet staging systems may be enhanced by the incorporation of additional data, including the presence of cytogenetic abnormalities and levels of serum ␤ 2 -microglobulin and albumin.
According to the WHO classification, lymphocytosis in CLL/SLL is defined as an ALC at least 10 ϫ 10 9 /L, but the diagnosis of CLL/SLL can still be made with a lower ALC if morphologic and immunophenotypic features are typical of CLL/SLL.
1 Several other definitions of lymphocytosis have also been used. In 1975, Rai et al 19 proposed a staging system in CLL defining lymphocytosis as an ALC at least 15 ϫ 10 9 /L. In a multivariate analysis, we identified ALC at least 30 ϫ 10 9 /L as an independent factor predicting shorter survival. This is consistent with results of other investigators who defined "smoldering CLL" as an ALC of less than 30 ϫ 10 9 /L. 20, 21 The higher rate of CD38 expression (36%) in patients in the low-ALC group (ALC Ͻ 5 ϫ 10 9 /L) in our study is consistent with a previous report 22 and with a higher expression of CD38 in the lymph nodes compared with bone marrow or peripheral blood in patients with CLL/SLL in another report.
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The strongest independent predictor of poor survival was the presence of a 17p or 6q deletion, with or without other cytogenetic abnormalities. These findings confirm those of earlier studies showing that 17p deletion 24 and 6q deletion 25 are associated with adverse prognosis in CLL/SLL. It has been suggested that 6q deletion may be an initial event in leukemogenesis, caused by the absence of an unidentified recessive tumor suppressor gene. As expected, older age was also an independent predictor of shorter survival (Table 2) . Older age has been associated with shorter survival in most studies, 26, 27 with the exception of one study demonstrating that younger and older patients with CLL had a similar probability of survival. 28 The disparity could be explained by the low death rate in both age groups in that study (26% for patients Յ 55 years and 19% for those Ͼ 55 years), 28 suggesting that the follow-up period should have continued until the death rate reached 50% in both groups. The third-strongest independent factor predicting survival was the ␤ 2 -microglobulin level, which is also consistent with previous reports. 29, 30 The clinical significance of albumin and creatinine may reflect the independent value of the microenvironment and comorbidities in predicting survival. The prognostic value of the remaining independent predictors of survival (ie, hepatomegaly, low hemoglobin level, and male sex; Table 2 ) is well established. Although the mutational status of the IgV H gene 31 predicted survival in univariate analysis, it was not an independent factor. In contrast to Abbreviations: F Ϯ P, fludarabine Ϯ prednisone; FC, fludarabine and cyclophosphamide; FM, fludarabine and mitoxantrone; FCR, fludarabine, cyclophosphamide, and rituximab; R-FCM, fludarabine, cyclophosphamide, mitoxantrone, and rituximab; R-FND, fludarabine, mitoxantrone, dexamathasone, and rituximab; R Ϯ GM, rituximab Ϯ granulocyte macrophage colony-stimulating factor; ALC, absolute lymphocyte count; NA, not applicable; ZAP-70, zeta-associated protein-70.
‫ء‬
P value indicates that not all treatment groups had identical pretreatment features. There were no significant differences between the treatment groups in age, performance status, platelet counts, level of creatinine or albumin, presence of hepatomegaly, and expression of ZAP-70. The treatment groups differed significantly in the remaining listed features.
†One to five patients were tested. Abbreviations: CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; F Ϯ P, fludarabine Ϯ prednisone; FC, fludarabine and cyclophosphamide; FM, fludarabine and mitoxantrone; FCR, fludarabine, cyclophosphamide, and rituximab; R-FCM, fludarabine, cyclophosphamide, mitoxantrone, and rituximab; R-FND, fludarabine, mitoxantrone, dexamathasone, and rituximab; R Ϯ GM, rituximab Ϯ granulocyte macrophage colony-stimulating factor; ALC, absolute lymphocyte count; FFS, failure-free survival.
previous reports, 32 expression of ZAP-70 did not correlate with survival in univariate and multivariate analyses; however, there were missing data, and the follow-up period in patients tested was short.
On the basis of the five most statistically significant independent factors (ie, 17p or 6q deletion with or without other cytogenetic abnormalities; age; and levels of ␤ 2 -microglobulin, albumin, and creatinine), a prognostic score was developed. Our proposed CLL/SLL prognostic score may supplement the well-established Rai and Binet staging systems, 19, 33 keeping in mind that more effective treatment strategies have become available over time, as well as the use of riskadapted therapies. Several other prognostic factors have been identified in CLL/SLL, and new markers are being validated in clinical trials.
34-39 Until these results become available, treatment decisions outside of clinical trials should conform to the NCI-sponsored Working Group criteria. 40 In the treatment of CLL/SLL, regimens containing rituximab and a nucleoside analog, such as FCR, R-FCM, or R-FND, were highly effective and were associated with superior rates of response and FFS. It is likely that these results will also translate into superior survival, although longer follow-up is needed. This speculation is supported by a Cox regression analysis in which, when treatment was added to the model (Table 2) , therapy other than FCR, R-FCM, or R-FND was an independent predictor of shorter survival (P Ͻ .0001). Rates of response, survival, and FFS did not differ by ALC group, suggesting that patients with CLL/SLL and ALCs less than 5 ϫ 10 9 /L should be treated similarly to those with higher ALCs.
The results of this report should be interpreted with caution because of (1) the retrospective nature of the analysis, (2) the long time interval during which different therapies were offered, and (3) the variation in selection criteria for the different regimens, which naturally resulted in strong interactions between various therapies and other characteristics (Table 3) . Another limitation is the difference in response criteria for CLL and SLL. Computed tomography scans were required for assessment of response in SLL, but they have not been uniformly utilized in CLL.
This study emphasizes the need for standardized, common response criteria for CLL/SLL. Patients with untreated CLL/SLL should be assessed using standard and new markers, including FISH analysis, IgV H , and ZAP-70. Future research should focus on using prognostic factors to assign risk-adapted therapies and prolonging FFS by optimizing maintenance therapy and developing strategies to eradicate minimal residual disease.
